New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells
Medical Xpress reports EASD meeting data on CBL-514, an experimental injection meant to make fat cells self-destruct. In a small phase 2 MRI subgroup, CBL-514 (n=23) versus placebo (n=17), with participants of BMI 22–30 kg/m2, visceral fat was 10.45% lower than baseline versus 11.76% higher on placebo. A developer scientist co-authored it. Less weight regain after stopping tirzepatide was seen only in rats; phase 3 is recruiting.
Why it matters: Relevant to Maryland adults weighing nonsurgical abdominal fat-reduction options and to clinicians who manage medical weight loss or refer patients for body contouring.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to medicalxpress.com. October 3, 2026.